SBIA
ATHE

Sheaff Brock Investment Advisors’s Alterity Therapeutics ATHE Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-173
Closed -$8K – 634
2015
Q4 		$8K Buy
+173
New +$8.8K ﹤0.01% 663

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
MFS
MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

Sheaff Brock Investment Advisors's ATHE Position: Q1 2016 in Review

Sheaff Brock Investment Advisors sold out of Alterity Therapeutics (ATHE) in Q1 2016, closing a stake of 173 shares — an estimated $8K sold.

Sheaff Brock Investment Advisors first reported a position in ATHE in Q4 2015 and held it in 1 quarter. The position peaked at $8K in Q4 2015. 14 funds tracked by Wall St. Rank hold ATHE as of Q1 2016.

  • Sheaff Brock Investment Advisors reported no remaining Alterity Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 173 Alterity Therapeutics shares in Q1 2016, an estimated $8K.
  • Sheaff Brock Investment Advisors first reported a position in Alterity Therapeutics in Q4 2015 and held it in 1 quarter.
  • Sheaff Brock Investment Advisors's Alterity Therapeutics position peaked at $8K in Q4 2015.
  • 14 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2016.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2016, filed 25 Apr 2016.